Sitagliptin DOC 25 mg film-coated tablets

Maa: Malta

Kieli: englanti

Lähde: Medicines Authority

Aktiivinen ainesosa:

SITAGLIPTIN

Saatavilla:

Doc Generici srl Via Turati, 40-20121, Milano, Italy

ATC-koodi:

A10BH01

INN (Kansainvälinen yleisnimi):

SITAGLIPTIN 25 mg

Lääkemuoto:

FILM-COATED TABLET

Koostumus:

SITAGLIPTIN 25 mg

Prescription tyyppi:

POM

Terapeuttinen alue:

DRUGS USED IN DIABETES

Tuoteyhteenveto:

Licence number in the source country: NOT APPLICAPABLE

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2020-04-03

Pakkausseloste

Page
1
of
5
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SITAGLIPTIN DOC 25 MG FILM-COATED TABLETS
Sitagliptin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What
SITAGLIPTIN DOC is and what it is used for
2.
What you need to know before you take SITAGLIPTIN DOC
3.
How to take SITAGLIPTIN DOC
4.
Possible side effects
5.
How to store SITAGLIPTIN DOC
6.
Contents of the pack and other information
1.
WHAT SITAGLIPTIN DOC IS AND WHAT IT IS USED FOR
SITAGLIPTIN DOC contains the active substance sitagliptin which is a
member of a class of
medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors)
that lowers blood sugar levels in
adult patients with type 2 diabetes mellitus.
This medicine helps to increase the levels of insulin produced after a
meal and decreases the amount
of sugar made by the body.
Your doctor has prescribed this medicine to help lower your blood
sugar, which is too high because of
your type 2 diabetes. This medicine can be used alone or in
combination with certain other medicines
(insulin, metformin, sulphonylureas, or glitazones) that lower blood
sugar, which you may already be
taking for your diabetes together with a food and exercise plan.
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should. Your body can
also make too much sugar.
When this happens, sugar (glucose) builds up in the blood. This can
lead to serious medical problems
lik

Valmisteyhteenveto

Page
1
of
16
1.
NAME OF THE MEDICINAL PRODUCT
SITAGLIPTIN DOC 25 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains sitagliptin hydrochloride monohydrate, equivalent
to 25 mg sitagliptin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Round, pink film-coated tablets of approximately 6.3 mm diameter.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult patients with type 2 diabetes mellitus, SITAGLIPTIN DOC is
indicated to improve
glycaemic control:
As monotherapy
•
in patients inadequately controlled by diet and exercise alone and for
whom metformin is
inappropriate due to contraindications or intolerance.
As dual oral therapy in combination with
•
Metformin when diet and exercise plus metformin alone do not provide
adequate glycaemic
control.
•
A sulphonylurea when diet and exercise plus maximal tolerated dose of
sulphonylurea alone
do not provide adequate glycaemic control and when metformin is
inappropriate due to
contraindications or intolerance.
•
A peroxisome proliferator-activated receptor gamma (PPAR
γ
) agonist (i.e. a
thiazolidinedione) when use of a PPAR
γ
agonist is appropriate and when diet and exercise
plus the PPAR
γ
agonist alone do not provide adequate glycaemic control.
As triple oral therapy in combination with
•
A sulphonylurea and metformin when diet and exercise plus dual therapy
with these
medicinal products do not provide adequately glycaemic control.
•
A PPAR
γ
agonist and metformin when use of a PPAR
γ
agonist is appropriate and when diet
and exercise plus dual therapy with these medicinal products do not
provide adequate
glycaemic control.
SITAGLIPTIN DOC is also indicated as add-on to insulin (with or
without metformin) when diet and
exercise plus stable dose of insulin do not provide adequate glycaemic
control.
Page
2
of
16
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dose is 100 mg sitagliptin once daily. When used in combination
with metformin and/or a PPAR